Fresh Tracks Therapeutics (FRTX) 10-Q/A 1 Sep 22 2022 Q2 Quarterly report (amended) Financial data

COVER PAGE

COVER PAGE - shares	6 Months Ended
	Jun. 30, 2022	Aug. 11, 2022
Cover [Abstract]
Document Type	10-Q/A
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-21088
Entity Registrant Name	BRICKELL BIOTECH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	93-0948554
Entity Address, Address Line One	5777 Central Avenue,
Entity Address, City or Town	Boulder,
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	720
Local Phone Number	505-4755
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	BBI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,873,965
Entity Central Index Key	0000819050
Document Fiscal Period Focus	Q2
Amendment Flag	true
Amendment Description	Subsequent to the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, originally filed with the Securities and Exchange Commission on August 11, 2022 (the “Original 10-Q”), the Company determined that certain of the information in the Original 10-Q had not been appropriately adjusted for the 1-for-45 reverse stock split that the Company had effected on July 5, 2022, after the end of the period covered by, but prior to the filing of, the Original Form 10-Q.
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 14,480	$ 26,884
Prepaid expenses and other current assets	3,771	2,716
Total current assets	18,251	29,600
Property and equipment, net	45	58
Contract asset, net of current portion	181	0
Operating lease right-of-use asset	30	59
Total assets	18,507	29,717
Current liabilities:
Accounts payable	1,263	1,605
Accrued liabilities	1,571	3,136
Lease liability, current portion	36	69
Total current liabilities	2,870	4,810
Commitments and contingencies (Note 7)
Redeemable preferred stock, $0.01 par value, 5,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 1 and 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	0	0
Stockholders’ equity:
Common stock, $0.01 par value, 300,000,000 shares authorized as of June 30, 2022 and December 31, 2021; 2,690,360 and 2,652,828 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	27	27
Additional paid-in capital	171,534	170,247
Accumulated deficit	(155,924)	(145,367)
Total stockholders’ equity	15,637	24,907
Total liabilities, redeemable preferred stock, and stockholders’ equity	$ 18,507	$ 29,717

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Temporary equity, par or stated value per share (in dollars per share)	$ 0.01	$ 0.01
Temporary equity, shares authorized	5,000,000	5,000,000
Temporary equity, shares outstanding	1	0
Temporary equity, shares issued	1	0
Common stock, par value (in usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	2,690,360	2,652,828
Common stock, shares outstanding	2,690,360	2,652,828

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Total revenue	$ 4,315	$ 151	$ 4,407	$ 168
Operating expenses:
Research and development	1,865	8,838	7,878	14,890
General and administrative	3,908	2,891	7,394	5,858
Total operating expenses	5,773	11,729	15,272	20,748
Loss from operations	(1,458)	(11,578)	(10,865)	(20,580)
Other income	313	459	314	490
Interest expense	(2)	(30)	(6)	(64)
Net loss attributable to common stockholders	$ (1,147)	$ (11,149)	$ (10,557)	$ (20,154)
Net loss per common share attributable to common stockholders, basic (in usd per share)	$ (0.43)	$ (7.29)	$ (3.98)	$ (14.03)
Net loss per common share attributable to common stockholders, diluted (in usd per share)	$ (0.43)	$ (7.29)	$ (3.98)	$ (14.03)
Weighted-average shares used to compute net loss per common share attributable to common stockholders, basic	2,655,251	1,530,142	2,654,046	1,436,591
Weighted-average shares used to compute net loss per common share attributable to common stockholders, diluted	2,655,251	1,530,142	2,654,046	1,436,591
Contract revenue
Total revenue	$ 4,315	$ 0	$ 4,315	$ 0
Royalty revenue
Total revenue	$ 0	$ 151	$ 92	$ 168

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF REDEEAMBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (UNAUDITED) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In-Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020	0
Beginning balance at Dec. 31, 2020	$ 0
Ending balance (in shares) at Mar. 31, 2021	0
Ending balance at Mar. 31, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020		1,190,032
Beginning balance at Dec. 31, 2020	27,135	$ 12	$ 133,016	$ (105,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of warrants (in shares)		276,553
Issuance of common stock upon exercise of warrants	8,969	$ 3	8,966
Issuance of stock (in shares)		24,079
Issuance of stock	1,628	$ 0	1,628
Issuance of common stock upon restricted stock unit settlement, net of shares withheld for taxes		2,141
Issuance of common stock upon restricted stock unit settlement, net of shares withheld for taxes	(52)	$ 0	(52)
Stock-based compensation	469		469
Net loss	(9,005)			(9,005)
Ending balance (in shares) at Mar. 31, 2021		1,492,805
Ending balance at Mar. 31, 2021	$ 29,144	$ 15	144,027	(114,898)
Beginning balance (in shares) at Dec. 31, 2020	0
Beginning balance at Dec. 31, 2020	$ 0
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Dec. 31, 2020		1,190,032
Beginning balance at Dec. 31, 2020	27,135	$ 12	133,016	(105,893)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(20,154)
Ending balance (in shares) at Jun. 30, 2021		1,598,782
Ending balance at Jun. 30, 2021	$ 22,353	$ 16	148,384	(126,047)
Beginning balance (in shares) at Mar. 31, 2021	0
Beginning balance at Mar. 31, 2021	$ 0
Ending balance (in shares) at Jun. 30, 2021	0
Ending balance at Jun. 30, 2021	$ 0
Beginning balance (in shares) at Mar. 31, 2021		1,492,805
Beginning balance at Mar. 31, 2021	29,144	$ 15	144,027	(114,898)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock (in shares)		105,977
Issuance of stock	3,937	$ 1	3,936
Stock-based compensation	421		421
Net loss	(11,149)			(11,149)
Ending balance (in shares) at Jun. 30, 2021		1,598,782
Ending balance at Jun. 30, 2021	$ 22,353	$ 16	148,384	(126,047)
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Mar. 31, 2022	0
Ending balance at Mar. 31, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021	2,652,828	2,652,828
Beginning balance at Dec. 31, 2021	$ 24,907	$ 27	170,247	(145,367)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	551		551
Net loss	(9,410)			(9,410)
Ending balance (in shares) at Mar. 31, 2022		2,652,828
Ending balance at Mar. 31, 2022	$ 16,048	$ 27	170,798	(154,777)
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Jun. 30, 2022	1
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021	2,652,828	2,652,828
Beginning balance at Dec. 31, 2021	$ 24,907	$ 27	170,247	(145,367)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (10,557)
Ending balance (in shares) at Jun. 30, 2022	2,690,360	2,690,360
Ending balance at Jun. 30, 2022	$ 15,637	$ 27	171,534	(155,924)
Beginning balance (in shares) at Mar. 31, 2022	0
Beginning balance at Mar. 31, 2022	$ 0
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of redeemable preferred stock	1
Ending balance (in shares) at Jun. 30, 2022	1
Ending balance at Jun. 30, 2022	$ 0
Beginning balance (in shares) at Mar. 31, 2022		2,652,828
Beginning balance at Mar. 31, 2022	16,048	$ 27	170,798	(154,777)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock (in shares)		31,557
Issuance of stock	131	$ 0	131
Common stock issued for cash under employee stock purchase plan (in shares)		5,975
Issuance of common stock for cash under employee stock purchase plan	29	$ 0	29
Stock-based compensation	576		576
Net loss	$ (1,147)			(1,147)
Ending balance (in shares) at Jun. 30, 2022	2,690,360	2,690,360
Ending balance at Jun. 30, 2022	$ 15,637	$ 27	$ 171,534	$ (155,924)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (UNAUDITED) (PARENTHETICAL) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$ 46	$ 259	$ 50

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,557)	$ (20,154)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,127	890
Depreciation	13	8
Gain on loan extinguishment	0	(437)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets, including long-term portion of contract asset	(1,240)	(1,092)
Accounts payable	(342)	1,932
Accrued liabilities	(1,510)	(1,352)
Net cash used in operating activities	(12,509)	(20,205)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	0	(36)
Net cash used in investing activities	0	(36)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of common stock, net of issuance costs	131	5,565
Payments of taxes related to net share settlement of equity awards	(55)	0
Proceeds from the issuance of commons stock under employee stock purchase program	29	0
Proceeds from the exercise of warrants	0	8,969
Net cash provided by financing activities	105	14,534
NET DECREASE IN CASH AND CASH EQUIVALENTS	(12,404)	(5,707)
CASH AND CASH EQUIVALENTS—BEGINNING	26,884	30,115
CASH AND CASH EQUIVALENTS—ENDING	14,480	24,408
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Forgiveness of Paycheck Protection Program loan	$ 0	$ 437

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF OPERATIONS	ORGANIZATION AND NATURE OF OPERATIONS Brickell Biotech, Inc. (the “Company” or “Brickell”) is a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. Brickell’s pipeline consists of several development-stage candidates and a cutting-edge platform with broad potential in autoimmune and inflammatory disorders. This includes: BBI-02, a novel, clinical-stage, potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation for treatment of autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and type 1 diabetes; BBI-10, a novel, preclinical-stage oral Stimulator of Interferon Genes (STING) inhibitor that has demonstrated dose-dependent cytokine reduction in nonclinical studies providing proof of mechanism for the potential treatment of autoinflammatory and rare genetic diseases; and a platform of next-generation DYRK, CDC2-like kinase (CLK), Leucine-Rich Repeat Kinase 2 (LRRK2), and TTK protein kinase (TTK), also known as Monopolar spindle 1 (Mps1) kinase, inhibitors with the potential to produce treatments for autoimmune, inflammatory, and other debilitating conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in senior leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis ® , Taltz ® , Gemzar ® , Prozac ® , Cymbalta ® , Juvederm ® , Pluvicto ® , and Sofpironium Bromide. Brickell’s strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative pharmaceutical products that Brickell believes can meaningfully benefit patients who are suffering from chronic, debilitating diseases that are underserved by available therapies. Reverse Stock Split (Restated) On July 5, 2022, the Company effected a 1-for-45 reverse stock split of outstanding shares of its common stock. All common stock share, per-share amounts, and other related balances and computations reported as of and prior to June 30, 2022 in the condensed consolidated financial statements and notes reflect the adjusted common stock share, per-share amounts, and other related balances and computations that were effective on and after July 5, 2022. Additional details of the reverse stock split are reported in Note 8. “ Capital Stock.” Liquidity and Capital Resources The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to in-license and develop product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the six months ended June 30, 2022, the Company had a net loss of $10.6 million and net cash used in operating activities of $12.5 million. As of June 30, 2022, the Company had cash and cash equivalents of $14.5 million and an accumulated deficit of $155.9 million. The Company believes that its cash and cash equivalents as of June 30, 2022, combined with $2.0 million from expected near-term payments from Botanix SB Inc. (“Botanix”) under the Asset Purchase Agreement (as defined in Note 4. “ Strategic Agreements ”), will be sufficient to fund its operations for at least the next 12 months. The Company expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. Additional funding will be required in the future to continue with the Company’s planned development and other activities. However, the Company may be unable to raise additional funds, which would have a negative impact on the Company’s business, financial condition, and the Company’s ability to develop its pipeline. To the extent that additional funds are raised through the sale of equity, the issuance of securities will result in dilution to the Company’s stockholders.

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	6 Months Ended
	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On July 5, 2022, the Company effected a 1-for-45 reverse stock split of outstanding shares of its common stock. Accordingly, all references to common stock share, per-share amounts, and other related balances and computations in the accompanying condensed consolidated financial statements and related notes have been adjusted to reflect the reverse stock split, on a retroactive basis, unless indicated otherwise. Subsequent to the filing of the Original 10-Q, the Company determined that certain components of the Company’s equity and disclosures of common stock share, per-share amounts, and other related balances and computations in the Original 10-Q should have been adjusted for the 1-for-45 reverse stock split that the Company had effected on July 5, 2022, after the end of the period covered by, but prior to the filing of, the Original Form 10-Q. Accordingly, all common stock share, per-share amounts, and other related balances and computations have been restated in the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, condensed consolidated statements of operations and condensed consolidated statements of redeemable preferred stock and stockholders’ equity for the three- and six-month periods ended June 30, 2022 and 2021, and certain notes related thereto. Because the par value per share of the Company’s common stock was not changed by the reverse stock split, historical amounts for common stock par value and additional paid-in capital have been adjusted retroactively to reflect the reverse stock split in the condensed consolidated balance sheets at June 30, 2022 and December 31, 2021, and in the condensed consolidated statements of redeemable preferred stock and stockholders’ equity for the three- and six-month periods ended June 30, 2022 and 2021. The following table illustrates the impact of the restatement of basic and diluted net loss per common share attributable to common stockholders on the condensed consolidated statements of operations: Three Months Ended Six Months Ended 2022 2021 2022 2021 As previously reported $ (0.01) $ (0.16) $ (0.09) $ (0.31) Adjustment $ (0.42) $ (7.13) $ (3.89) $ (13.72) As restated $ (0.43) $ (7.29) $ (3.98) $ (14.03) The following table illustrates the impact of the restatement of common stock par value and additional paid-in capital on the condensed consolidated balance sheets: June 30, 2022 December 31, 2021 Common Stock Additional Paid-In Capital Common Stock Additional Paid-In Capital As previously reported $ 1,211 $ 170,350 $ 1,194 $ 169,080 Adjustment (1,184) 1,184 (1,167) 1,167 As restated $ 27 $ 171,534 $ 27 $ 170,247

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc. (“Brickell Subsidiary”), and are presented in United States (“U.S.”) dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the SEC for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022, for any other interim period, or for any other future period. The condensed consolidated balance sheet as of December 31, 2021 has been derived from audited financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation. The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein. Use of Estimates The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions. Risks and Uncertainties The Company’s business is subject to significant risks common to early-stage companies in the pharmaceutical industry including, but not limited to, the ability to develop appropriate formulations, scale up and produce the compounds; dependence on collaborative parties; uncertainties associated with obtaining and enforcing patents and other intellectual property rights; clinical implementation and success; the lengthy and expensive regulatory approval process; compliance with regulatory and other legal requirements; competition from other products; uncertainty of broad adoption of its approved products, if any, by physicians and patients; significant competition; ability to manage third-party manufacturers, suppliers, contract research organizations, business partners and other alliances; and obtaining additional financing to fund the Company’s efforts. The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to develop its product candidates. There can be no assurance that such financing will be available or will be at terms acceptable to the Company. Fair Value Measurements Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market, or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy distinguishes between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs). The hierarchy is summarized in the three broad levels listed below: Level 1 —quoted prices in active markets for identical assets and liabilities Level 2 —other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.) Level 3 —significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities) The following table sets forth the fair value of the Company’s financial assets measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): Level 1 June 30, December 31, Assets: Money market funds $ 13,480 $ 25,875 Fair Value of Financial Instruments The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein: Money Market Funds— The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy). The carrying values of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value due to the short-term maturity of those items. Revenue Recognition The Company has recognized revenue primarily from royalty fees received under the Kaken Agreement and upfront fees, research reimbursements, and sublicense income received under the Asset Purchase Agreement described in Note 4. “ Strategic Agreements. ” The terms of the agreements may include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones, and various sales-based payments. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company utilizes judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Contract Revenue The Company evaluates its contracts, including asset sale arrangements that involve the Company’s rights to intellectual property, to determine whether they are outputs of the Company’s ordinary activities and whether the counterparty meets the definition of a customer. If the arrangement is determined to be a contract with a customer and the goods or services sold are determined to be distinct from other performance obligations identified in the arrangement, the Company recognizes revenue primarily from non-refundable upfront fees, milestone payments, and sales-based payments allocated to the goods or services when (or as) control is transferred to the customer, and the customer can use and benefit from the goods or services. Licenses of Intellectual Property If a license for the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue when the license is transferred to the customer, and the customer can use and benefit from the license. Milestones At the inception of each arrangement that includes milestone payments (variable consideration), excluding sales-based milestone payments discussed below, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The most likely amount method is generally utilized when there are only two possible outcomes and represents the Company’s best estimate of the single most likely outcome to be achieved. If it is probable that a significant revenue reversal would not occur, the variable consideration for the associated milestone is included in the transaction price. Milestone payments contingent on regulatory approvals that are not within the Company and the Company’s collaboration partner’s control, as applicable, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the variable consideration. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment. Sales-Based Payments For license arrangements that include sales-based payments such as royalties or milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the sales-based payments relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the sales-based payment has been allocated has been satisfied (or partially satisfied). Sales-based payments received under license arrangements are recorded as royalty revenue in the Company’s condensed consolidated statements of operations. For non-license arrangements that include sales-based payments, including earnout payments and milestone payments based on the level of sales, the Company estimates the sales-based payments (variable consideration) to be achieved and recognizes revenue to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company may use either the most likely amount, as described above, or the expected value method, in making such estimates based on the nature of the payment to be received and whether there is a wide range of outcomes or only two possible outcomes. The expected value method represents the sum of probability-weighted amounts in a range of possible consideration amounts. The Company bases its estimates using the applicable method described above on factors such as, but not limited to, required regulatory approvals, historical sales levels, market events and projections, and other factors as appropriate. The Company updates its estimates at each reporting period based on actual results and future expectations as necessary. Contract Asset For non-license arrangements involving the upfront sale and transfer of the Company’s intellectual property rights, the Company recognizes estimated variable consideration as revenue as discussed above before the customer pays consideration or before payment is due. The excess revenue recognized is presented as a contract asset on the Company’s condensed consolidated balance sheets. Actual amounts paid or due by the customer are recorded as a reduction to the contract asset. Any revisions to the Company’s estimated revenue based on actual results and future expectations are recognized as an adjustment to the contract asset. Research and Development Research and development costs are charged to expense when incurred and consist of costs incurred for independent and collaboration research and development activities. The major components of research and development costs include formulation development, nonclinical studies, clinical studies, clinical manufacturing costs, in-licensing fees for development-stage assets, salaries and employee benefits, and allocations of various overhead and occupancy costs. Research costs typically consist of applied research, preclinical, and toxicology work. Pharmaceutical manufacturing development costs consist of product formulation, chemical analysis, and the transfer and scale-up of manufacturing at contract manufacturers. Assets acquired (or in-licensed) that are utilized in research and development that have no alternative future use are expensed as incurred. Milestone payments related to the Company’s acquired (or in-licensed) assets are recorded as research and development expenses when probable and reasonably estimable. The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company’s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expenses when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects. Clinical Trial Accruals Expense accruals related to clinical trials are based on the Company’s estimates of services received and efforts expended pursuant to contracts with multiple research institutions and third-party clinical research organizations that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing costs, the Company estimates the period over which services will be performed and the level of effort to be expended in each period based upon patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results. Net Loss per Share (Restated) Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net income by the weighted-average number of common shares outstanding and the impact of all potentially dilutive common shares. Diluted net loss per share is the same as basic net loss per share, as the effects of potentially dilutive securities are anti-dilutive for all periods presented. The following table sets forth the potential common shares excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive: Three and Six Months Ended 2022 2021 Outstanding warrants 621,063 621,063 Outstanding options 232,084 149,248 Unvested restricted stock units — 1,054 Total 853,147 771,365 Leases The Company determines if an arrangement is a lease at inception. Operating leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company does not currently hold any financing leases. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of one year or less and not to separate lease components and non-lease components for long-term real estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate in determining the present value of lease payments. The Company’s headquarters operating lease has one single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations. Redeemable Preferred Stock The Company issued one share of redeemable preferred stock in May 2022. The redeemable preferred stock contained provisions that required redemption under circumstances that were outside of the Company’s control and was classified as a mezzanine instrument outside of the Company’s capital accounts. The share of redeemable preferred stock was sold to one investor for $10 and was subsequently redeemed in July 2022, as described further in Note 8. “ Capital Stock. ” New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards has had or will have a material impact on the Company's condensed consolidated financial statements or disclosures.

STRATEGIC AGREEMENTS

STRATEGIC AGREEMENTS	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
STRATEGIC AGREEMENTS	STRATEGIC AGREEMENTS Exclusive License and Development Agreement with Carna On February 2, 2022, the Company entered into an Exclusive License Agreement (the “Carna License Agreement”) with Carna Biosciences, Inc. (“Carna”), pursuant to which the Company acquired exclusive, worldwide rights to research, develop, and comme rcialize Carna’s portfolio of novel STING inhibitors. In accordance with the terms of the Carna License Agreement, in exchange for the licensed rights, the Company made a one -time cash payment of $2.0 million, which was recorded as research and development expenses in the condensed consolidated statements of operations during the six months ended June 30, 2022. The Carna License Agreement provides that the Company will make success-based payments to Carna of up to $258.0 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Carna License Agreement provides that the Company will pay Carna tiered royalty payments ranging from mid-single digits up to 10% of net sales. All of the contingent payments and royalties are payable in cash in U.S. Dollars. Under the terms of the Carna License Agreement, the Company is responsible for, and bears the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds. As of June 30, 2022 and through the date of this Quarterly Report, the Company has not yet made any payments or recorded any liabilities related to the specified development, regulatory, and commercial milestones or royalties on net sales pursuant to the Carna License Agreement. License and Development Agreement with Voronoi (Restated) On August 27, 2021, the Company entered into a License and Development Agreement (the “Voronoi License Agreement”) with Voronoi Inc. (“Voronoi”), pursuant to which the Company acquired exclusive, worldwide rights to research, develop, and commercialize BBI-02, a novel, clinical-stage, potential first-in-class, oral DYRK1A inhibitor, and other next-generation kinase inhibitors. In accordance with the terms of the Voronoi License Agreement, in exchange for the licensed rights, the Company made a one-time payment of $2.5 million in cash and issued $2.0 million, or 62,597 shares, of its common stock to Voronoi. With respect to BBI-02, the Voronoi License Agreement provides that the Company will make payments to Voronoi of up to $211.0 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. With respect to the next-generation compounds arising from the novel kinase inhibitor platform, the Company will make payments to Voronoi of up to $107.5 million in the aggregate contingent upon achievement of specified development, regulatory, and commercial milestones. Further, the Voronoi License Agreement provides that the Company will pay Voronoi tiered royalty payments ranging from low-single digits up to 10% of net sales of products arising from the DYRK1A inhibitor programs and next-generation kinase inhibitor platform. All of the contingent payments and royalties are payable in cash in U.S. Dollars, except for $1.0 million of the development and regulatory milestone payments, which amount is payable in equivalent shares of the Company’s common stock. Under the terms of the Voronoi License Agreement, the Company is responsible for, and bears the future costs of, all development and commercialization activities, including patenting, related to all the licensed compounds. As of June 30, 2022 and through the date of this Quarterly Report, the Company has not yet made any payments or recorded any liabilities related to the specified development, regulatory, and commercial milestones or royalties on net sales pursuant to the Voronoi License Agreement. Asset Purchase Agreement with Botanix On May 3, 2022 (the “Effective Date”), the Company and Brickell Subsidiary entered into an asset purchase agreement with Botanix and Botanix Pharmaceuticals Limited (the “Asset Purchase Agreement”), pursuant to which Botanix acquired and assumed control of all rights, title, and interests to assets primarily related to the proprietary compound sofpironium bromide that were owned and/or licensed by the Company or Brickell Subsidiary (the “Assets”). The Company had previously entered into a License Agreement with Bodor Laboratories, Inc. (“Bodor”), dated December 15, 2012 (last amended in February 2020) that provided the Company with a worldwide exclusive license to develop, manufacture, market, sell, and sublicense products containing sofpironium bromide through which the Assets were developed (the “Amended and Restated License Agreement”). As a result of the Asset Purchase Agreement, Botanix is now responsible for all further research, development, and commercialization of sofpironium bromide globally and replaced the Company as the exclusive licensee under the Amended and Restated License Agreement. In accordance with the sublicense rights provided to the Company under the Amended and Restated License Agreement, the Company also previously entered into a License, Development, and Commercialization Agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”), dated as of March 31, 2015 (as amended in May 2018, the “Kaken Agreement”), under which the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the sofpironium bromide compound in Japan and certain other Asian countries (the “Territory”). In exchange for the sublicense, the Company was entitled to receive aggregate payments of up to $10.0 million upon the achievement of specified development milestones, which was earned and received in 2017 and 2018, and up to $19.0 million upon the achievement of sales-based milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. In September 2020, Kaken received regulatory approval in Japan to manufacture and market sofpironium bromide gel, 5% (ECCLOCK ® ) for the treatment of primary axillary hyperhidrosis, and as a result, the Company began recognizing royalty revenue earned on a percentage of net sales of ECCLOCK in Japan. Pursuant to the Asset Purchase Agreement, the Kaken Agreement was also assigned to Botanix, which replaced the Company as the exclusive sub-licensor to Kaken. During the three and six months ended June 30, 2022, prior to entering into the Asset Purchase Agreement, the Company recognized royalty revenue of $0 and $0.2 million, respectively, under the Kaken Agreement. During the three and six months ended June 30, 2021, the Company recognized royalty revenue of $0.1 million and $0.2 million, respectively. The Company determined that the development of and ultimate sale and assignment of rights to the Assets is an output of the Company’s ordinary activities and Botanix is a customer as it relates to the sale of the Assets and related activities. In accordance with the terms of the Asset Purchase Agreement, in exchange for the Assets, the Company (i) received an upfront payment at closing in the amount of $3.0 million, (ii) is to be reimbursed for certain recent development expenditures in advancement of the Assets, and (iii) will receive from Botanix contingent near-term milestone payments of (a) $2.0 million upon the acceptance by the U.S. Food and Drug Administration (“FDA”) of the filing of a new drug application (“NDA”) for sofpironium bromide gel, 15%, and (b) $4.0 million if marketing approval in the U.S. for sofpironium bromide gel, 15%, is received on or before September 30, 2023, or $2.5 million if such marketing approval is received after September 30, 2023 but on or before February 17, 2024. The Company also is eligible to receive additional success-based regulatory and sales milestone payments of up to $168 million. Further, the Company will receive tiered earnout payments ranging from high-single digits to mid-teen digits on net sales of sofpironium bromide gel (the “Earnout Payments”). The Asset Purchase Agreement also provides that Botanix will pay to the Company a portion of the sales-based milestone payments and royalties that Botanix receives from Kaken under the Kaken Agreement (together, the “Sublicense Income”). During the three and six months ended June 30, 2022, the Company recorded contract revenue for the upfront payment received by the Company from Botanix of $3.0 million, reimbursed development expenditures from Botanix under the Asset Purchase Agreement of $0.6 million, and fees for consulting services the Company provided under the TSA (as defined below) of $0.4 million. Additionally, during the three and six months ended June 30, 2022, the Company recognized contract revenue of $0.3 million related to the Sublicense Income, which represents the Company’s estimate of payments that will be earned by the Company in the applicable period from royalties Botanix will receive from Kaken to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Such payments vary based on net sales that are impacted by a wide variety of market and other factors and, as such, the Company utilized the expected value approach, which the Company believes will best predict the amount of consideration to which it will be entitled. In relation to the sales-based milestone payments that Botanix may receive from Kaken in the future, the Company utilized the most likely amount method and determined it is not yet probable that the Company will receive any payments from Botanix in relation to such milestone payments. Therefore, the Company determined that such milestone payments are fully constrained as of June 30, 2022, and, as such, have not yet been recognized as contract revenue. All other consideration due under the Asset Purchase Agreement is contingent upon certain regulatory approvals and future sales subsequent to such regulatory approvals or is based upon future sales that the Company determined are not yet probable due to such revenues being highly susceptible to factors outside of the Company’s influence and uncertainty about the amount of such consideration that will not be resolved for an extended period of time. Therefore, the Company determined that such variable consideration amounts are fully constrained as of June 30, 2022, and as such, did not recognize such amounts as contract revenue. With respect to the recognition of contract revenue for the Sublicense Income based on future royalties that will be due to Botanix from Kaken, certain amounts are not yet due from Botanix. Therefore, the Company has recorded a contract asset equal to the amount of revenue recognized to date related to the Sublicense Income, less the amount of payments received from or due by Botanix in relation to the Sublicense Income to date. As of June 30, 2022, the contract asset related to the Sublicense Income is $0.3 million, of which $0.2 million is included within prepaid expenses and other current assets in the condensed consolidated balance sheet. Transition Services Agreement with Botanix In connection with the sale of the Assets, on the Effective Date, the Company and Botanix entered into a transition services agreement (the “TSA”) whereby the Company is providing consulting services as an independent contractor to Botanix in support of and through filing and potential approval of the U.S. NDA for sofpironium bromide gel, 15%. In accordance with the terms of the TSA, in exchange for providing these services, the Company will receive from Botanix, (i) prior to the acceptance of the filing by the FDA of such NDA, a fixed monthly amount of $71 thousand, and (ii) after the acceptance of the filing by the FDA of such NDA, a variable amount based upon actual hours worked, in each case plus related fees and expenses of the Company’s advisors (plus a 5% administrative fee) and the Company’s out-of-pocket expenses. During the three and six months ended June 30, 2022, the Company recognized contract revenue of $0.4 million related to these services. Agreements with Bodor In connection with the sale of the Assets, on the Effective Date, the Company, Brickell Subsidiary, and Bodor entered into an agreement (the “Rights Agreement”) to clarify that the Company and Brickell Subsidiary have the power and authority under the Amended and Restated License Agreement to enter into the Asset Purchase Agreement and the TSA, and that Botanix would assume the Amended and Restated License Agreement pursuant to the Asset Purchase Agreement. The Rights Agreement includes a general release of claims and no admission of liability between the parties. Pursuant to such Rights Agreement, the Company has agreed to pay Bodor (i) 18% of the amount of each payment actually received by the Company from Botanix for upfront and milestone payments under the Asset Purchase Agreement, as well as (ii) certain tiered payments, set as a percentage ranging from mid-single digits to low-teen digits, of the actual amount of each of the applicable Earnout Payments received by the Company from Botanix. During the three and six months ended June 30, 2022, the Company incurred $0.5 million of general and administrative expenses for payments due to Bodor.

DETAILED ACCOUNT BALANCES

DETAILED ACCOUNT BALANCES	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
DETAILED ACCOUNT BALANCES	DETAILED ACCOUNT BALANCES Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, Prepaid clinical trial costs $ 2,390 $ 1,443 Prepaid insurance 694 921 Accounts receivable 358 125 Other prepaid expenses 170 168 Contract asset 152 — Other short-term assets 7 59 Total $ 3,771 $ 2,716 Accrued liabilities consisted of the following (in thousands): June 30, December 31, Accrued compensation $ 1,016 $ 1,861 Accrued professional fees 382 452 Accrued contracted research and development services 173 823 Total $ 1,571 $ 3,136

NOTE PAYABLE

NOTE PAYABLE	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
NOTE PAYABLE	NOTE PAYABLE On April 15, 2020, the Company executed an unsecured promissory note to IberiaBank (the “PPP Loan”) pursuant to the U.S. Small Business Administration’s Paycheck Protection Program (the “PPP”) under Division A, Title I of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Company used the PPP Loan proceeds in the principal amount of $0.4 million and bearing interest at a fixed rate of 1.00% per annum to cover payroll costs and certain other permitted costs in accordance with the relevant terms and conditions of the CARES Act. In January 2021, the Company applied for forgiveness of the full amount of the PPP Loan, which was forgiven in full in June 2021. As a result, during the six months ended June 30, 2021, the Company recognized a gain on extinguishment of debt of approximately $0.4 million in the condensed consolidated statements of operations within the line “Other income.”

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Operating Lease In August 2016, the Company entered into a multi-year, noncancelable lease for its Colorado-based office space, which was amended in June 2021 to, among other things, extend the lease term to December 31, 2022 (as amended, the “Boulder Lease”). Under the terms of the Boulder Lease, the Company may, at its option, renew the Boulder Lease for two additional terms of three years each, with monthly rent payments determined at the time of renewal at the lower of $6,076 per month or current market rental rates. The Company recognized a right-of-use asset and corresponding lease liability. Minimum base lease payments under the Boulder Lease are recognized on a straight-line basis over the full term of the lease. In addition to base rental payments included in the contractual obligations table below, the Company is responsible for its pro rata share of the operating expenses for the building, which includes common area maintenance, utilities, property taxes, and insurance. Upon modification of the Boulder Lease, the Company reassessed classification of the lease and determined that the lease still met the criteria to be classified as an operating lease. Furthermore, the Company remeasured the lease liability as of the effective date by calculating the present value of the new lease payments, discounted at the Company’s updated incremental borrowing rate of 11.0%, over the extended term of 18 months. The operating expenses are variable and are not included in the present value determination of the lease liability. Because the Company was not reasonably certain to exercise the renewal option, the option was not considered in determining the lease term, and associated potential additional payments were excluded from lease payments. The following is a summary of the contractual obligations related to operating lease commitments as of June 30, 2022 (in thousands): Total maturities, through December 31, 2022 $ 37 Less imputed interest (1) Present value of lease liability $ 36 Licensing and Other Agreements Refer to Note 4. “ Strategic Agreements ” for more information about the Company’s obligations under its licensing and other agreements.

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
CAPITAL STOCK	CAPITAL STOCK (RESTATED) Reverse Stock Split On June 30, 2022, the stockholders of the Company approved an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock. The Company effected the reverse stock split at a split ratio of 1-for-45 on July 5, 2022, at which date each forty-five (45) shares of common stock issued and outstanding immediately prior to the reverse stock split were automatically reclassified, combined, and converted into one (1) validly issued, fully paid and non-assessable share of the Company’s common stock, subject to the treatment of fractional share interests as described below. Proportional adjustments were made to the number of shares of the Company’s common stock subject to outstanding equity awards and warrants, as well as the applicable exercise price. Proportional adjustments were also made to the reserve of shares available for future issuance under the Company’s equity incentive plans and the Brickell Biotech, Inc. Employee Stock Purchase Plan (the “ESPP”). No fractional shares were issued in connection with the reverse stock split. All fractional shares were aggregated and sold at the then-prevailing prices on The Nasdaq Capital Market on behalf of those stockholders who would otherwise be entitled to receive a fractional share as a result of the reverse stock split. After completion of such sale, stockholders who would have been entitled to a fractional share instead received a cash payment in an amount equal to their respective pro rata shares of the total proceeds of that sale net of any brokerage costs incurred to sell such stock. All common stock share, per-share amounts, and other related balances and computations reported as of and prior to June 30, 2022 in the condensed consolidated financial statements and notes thereto give effect to the 1-for-45 reverse stock split of our outstanding shares of common stock that occurred on July 5, 2022. The number of shares of our common stock authorized for issuance was not affected by the reverse stock split and was not proportionally decreased. Common Stock Under the Company’s amended and restated certificate of incorporation, the Company’s board of directors has the authority to issue up to 300,000,000 shares of common stock with a par value of $0.01 per share. Each share of the Company’s common stock is entitled to one vote, and the holders of the Company’s common stock are entitled to receive dividends when and as declared or paid by its board of directors. The Company had reserved authorized shares of common stock for future issuance as of June 30, 2022 as follows: June 30, Common stock warrants 621,063 Common stock options outstanding 232,084 Shares available for grant under the Omnibus Plan 125,075 Shares available for grant under the Employee Stock Purchase Plan 48,484 Total 1,026,706 Public Offerings of Common Stock and Warrants In October 2021, the Company completed a sale of 672,521 shares of its common stock at a public offering price of $17.10 per share in an underwritten public offering (the “October 2021 Offering”). The October 2021 Offering resulted in net proceeds of approximately $10.3 million, after deducting the underwriting discount and offering expenses payable by the Company. In July 2021, the Company completed a sale of 288,530 shares of its common stock at a public offering price of $27.90 per share in an underwritten public offering (the “July 2021 Offering”). The July 2021 Offering resulted in net proceeds of approximately $7.3 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. In October 2020, the Company completed a sale of 422,300 shares of its common stock, and, to certain investors, pre-funded warrants to purchase 40,663 shares of its common stock, and accompanying common stock warrants to purchase up to an aggregate of 462,979 shares of its common stock (the “October 2020 Offering”). Each share of common stock and pre-funded warrant to purchase one share of the Company’s common stock was sold together with a common warrant to purchase one share of the Company’s common stock. The public offering price of each share of the Company’s common stock and accompanying common warrant was $32.40 and $32.35 for each pre-funded warrant and accompanying common warrant, respectively. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The common warrants are exercisable at a price of $32.40 per share of the Company’s common stock and will expire five years from the date of issuance. The pre-funded warrants were exercised in October 2020 at an exercise price of $0.04 per share of the Company’s common stock. The October 2020 Offering resulted in net proceeds of approximately $13.7 million to the Company after deducting underwriting commissions and discounts and other offering expenses payable by the Company of $1.3 million and excluding the proceeds from the exercise of the warrants. During the six months ended June 30, 2021, 276,165 common warrants associated with the October 2020 Offering were exercised at a weighted-average exercise price of $32.40 per share, resulting in aggregate proceeds of approximately $8.9 million. In June 2020, the Company completed a sale of 328,669 shares of its common stock, and, to certain investors, pre-funded warrants to purchase 60,220 shares of its common stock, and accompanying common stock warrants to purchase up to an aggregate of 388,920 shares of its common stock (the “June 2020 Offering”). Each share of common stock and pre-funded warrant to purchase one share of common stock was sold together with a common warrant to purchase one share of common stock. The public offering price of each share of common stock and accompanying common warrant was $51.75 and $51.70 for each pre-funded warrant and accompanying common warrant, respectively. The shares of common stock and pre-funded warrants, and the accompanying common warrants, were issued separately and were immediately separable upon issuance. The pre-funded warrants were exercised in the third quarter of 2020 at an exercise price of $0.04 per share of common stock. The common warrants were immediately exercisable at a price of $56.25 per share of common stock and will expire five years from the date of issuance. The June 2020 Offering resulted in approximately $18.7 million of net proceeds to the Company after deducting underwriting commissions and discounts and other offering expenses payable by the Company of $1.4 million and excluding the proceeds from the exercise of the warrants. Certain officers of the Company participated in the June 2020 Offering by purchasing an aggregate purchase price of $0.2 million of the Company's common stock and warrants. During the six months ended June 30, 2021, 388 common warrants associated with the June 2020 Offering were exercised at a weighted-average exercise price of $56.25 per share, resulting in aggregate proceeds of approximately $22 thousand. The Company has used and is using the remaining net proceeds from its common stock offerings for research and development, including clinical trials, working capital, and general corporate purposes. At Market Issuance Sales Agreements In March 2021, the Company entered into an At Market Issuance Sales Agreement (the “2021 ATM Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”) and William Blair & Company, L.L.C. as the Company’s sales agents (the “Agents”). Pursuant to the terms of the 2021 ATM Agreement, the Company may sell from time to time through the Agents shares of its common stock having an aggregate offering price of up to $50.0 million. Such shares are issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-254037). Sales of the shares are made by means of ordinary brokers’ transactions on The Nasdaq Capital Market at market prices or as otherwise agreed by the Company and the Agents. Under the terms of the 2021 ATM Agreement, the Company may also sell the shares from time to time to an Agent as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the shares to an Agent as principal would be pursuant to the terms of a separate placement notice between the Company and such Agent. During the three and six months ended June 30, 2022, the Company sold 31,557 shares of common stock under the 2021 ATM Agreement at a weighted-average price of $5.61 per share, for aggregate net proceeds of $0.2 million, after giving effect to a 3% commission to the Agents. During the three and six months ended June 30, 2021, the Company sold 88,077 shares of common stock under the 2021 ATM Agreement at a weighted-average price of $40.18 per share, for aggregate net proceeds of $3.4 million, after giving effect to a 3% commission to the Agents. As of June 30, 2022, approximately $45.9 million of shares of common stock were remaining, but had not yet been sold by the Company under the 2021 ATM Agreement. In April 2020, the Company entered into an At Market Issuance Sales Agreement (the “2020 ATM Agreement” and, together with the 2021 ATM Agreement, the “ATM Agreements”) with Oppenheimer as the Company’s sales agent. Pursuant to the terms of the 2020 ATM Agreement, the Company may sell from time to time through Oppenheimer shares of its common stock having an aggregate offering price of up to $8.0 million. Such shares are issued pursuant to the Company’s shelf registration statement on Form S-3 (Registration No. 333-236353). Sales of the shares are made by means of ordinary brokers’ transactions on The Nasdaq Capital Market at market prices or as otherwise agreed by the Company and Oppenheimer. Under the terms of the 2020 ATM Agreement, the Company may also sell the shares from time to time to Oppenheimer as principal for its own account at a price to be agreed upon at the time of sale. Any sale of the shares to Oppenheimer as principal would be pursuant to the terms of a separate placement notice between the Company and Oppenheimer. During the three and six months ended June 30, 2022, no sales of common stock under the 2020 ATM Agreement occurred. During the three months ended June 30, 2021, the Company sold 122 shares of its common stock under the 2020 ATM Agreement at a weighted-average price of $52.25 per share, for aggregate net proceeds of approximately $6.2 thousand, after giving effect to a 3% commission to Oppenheimer as agent. During the six months ended June 30, 2021, the Company sold 24,201 shares of its common stock under the 2020 ATM Agreement at a weighted-average price of $69.62 per share, for aggregate net proceeds of approximately $1.6 million, after giving effect to a 3% commission to Oppenheimer as agent. As of June 30, 2022, approximately $2.6 million of shares of common stock were remaining, but had not yet been sold by the Company under the 2020 ATM Agreement. The Company is subject to the SEC’s “baby shelf rules,” which prohibit companies with a public float of less than $75 million from issuing securities under a shelf registration statement in excess of one-third of such company’s public float in a 12-month period. These rules may limit future issuances of shares by the Company under the ATM Agreements or other common stock offerings. Private Placement Offerings In February 2020, the Company and Lincoln Park Capital Fund, LLC (“Lincoln Park”) entered into (i) a securities purchase agreement (the “Securities Purchase Agreement”); (ii) a purchase agreement (the “Purchase Agreement”); and (iii) a registration rights agreement (the “Registration Rights Agreement”). Pursuant to the Securities Purchase Agreement, Lincoln Park purchased, and the Company sold, (i) an aggregate of 21,111 shares of common stock (the “Common Shares”); (ii) a warrant to initially purchase an aggregate of up to 13,476 shares of common stock at an exercise price of $0.45 per share (the “Series A Warrant”); and (iii) a warrant to initially purchase an aggregate of up to 34,588 shares of common stock at an exercise price of $52.20 per share (the “Series B Warrant,” and together with the Series A Warrant, the “Warrants”). The aggregate gross purchase price for the Common Shares and the Warrants was $2.0 million. Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $28.0 million in the aggregate of shares of common stock. In order to retain maximum flexibility to issue and sell up to the maximum of $28.0 million of the Company’s common stock under the Purchase Agreement, the Company sought and, at its annual meeting on April 19, 2021, received, stockholder approval for the sale and issuance of common stock in connection with the Purchase Agreement under Nasdaq Listing Rule 5635(d). Sales of common stock by the Company will be subject to certain limitations, and may occur from time to time, at the Company’s sole discretion, over the 36-month period commencing on August 14, 2020 (the “Commencement Date”). Following the Commencement Date, under the Purchase Agreement, on any business day selected by the Company, the Company may direct Lincoln Park to purchase up to 2,222 shares of common stock on such business day (each, a “Regular Purchase”), provided, however, that (i) the Regular Purchase may be increased to up to 2,777 shares, provided that the closing sale price of the common stock is not below $3.00 on the purchase date; and (ii) the Regular Purchase may be increased to up to 3,333 shares, provided that the closing sale price of the common stock is not below $5.00 on the purchase date. In each case, Lincoln Park’s maximum commitment in any single Regular Purchase may not exceed $1,000,000. The purchase price per share for each such Regular Purchase will be based on prevailing market prices of common stock immediately preceding the time of sale. In addition to Regular Purchases, the Company may direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if it would result in Lincoln Park beneficially owning more than 9.99% of the outstanding shares of common stock. During the three and six months ended June 30, 2022, no sales of common stock under the Purchase Agreement occurred. During the three and six months ended June 30, 2021, the Company sold to Lincoln Park 17,778 shares under the Purchase Agreement at a weighted-average price of $36.62 per share, for aggregate net proceeds of $0.6 million. As of June 30, 2022, approximately $26.9 million of shares of common stock were remaining, but had not yet been sold by the Company under the Purchase Agreement. However, only 57,751 of such shares (less than $175,000 of shares assuming a sale date of August 11, 2022) have been registered by the Company under the Securities Act of 1933, as amended. The Company agreed with Lincoln Park that it will not enter into any “variable rate” transactions with any third party, subject to certain exceptions, for a period defined in the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. The Securities Purchase Agreement, the Purchase Agreement, and the Registration Rights Agreement contain customary representations, warranties, agreements, and conditions to completing future sale transactions, indemnification rights, and obligations of the parties. Preferred Stock Under the Company’s amended and restated certificate of incorporation, the Company’s board of directors has the authority to issue up to 5,000,000 shares of preferred stock with a par value of $0.01 per share, at its discretion, in one or more classes or series and to fix the powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption, and liquidation preferences, without further vote or action by the Company’s stockholders. On May 25, 2022, the Company issued and sold one share of the Company’s preferred stock that was designated as Series A Preferred Stock (the “Series A Preferred Stock”) for a nominal amount. As of June 30, 2022, the outstanding share of Series A Preferred Stock had 80,000,000 votes exclusively with respect to any proposal to amend the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. The terms of the Series A Preferred Stock provided that it would be voted, without action by the holder, on any such proposal in the same proportion as shares of the Company’s common stock were voted. The Series A Preferred Stock otherwise had no voting rights except as otherwise required by the General Corporation Law of the State of Delaware. The Series A Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company and had no rights with respect to any distribution of assets of the Company, including upon a liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company, whether voluntarily or involuntarily. The holder of the Series A Preferred Stock was not entitled to receive dividends of any kind. The Series A Preferred Stock was redeemed in whole on July 5, 2022 upon the effectiveness of the amendment to the Certificate of Incorporation implementing the reverse stock split. Other than the one share of the Company’s Series A Preferred Stock outstanding as of June 30, 2022, as of such date the Company had not issued or designated the rights, preferences, or privileges of any other class or series of preferred stock.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION (RESTATED) Equity Incentive Plans On April 20, 2020, the Company’s stockholders approved the 2020 Omnibus Long-Term Incentive Plan (the “Omnibus Plan”), which replaced, with respect to new award grants, the Company’s 2009 Equity Incentive Plan, as amended and restated (the “2009 Plan”), and the Vical Equity Incentive Plan (the “Vical Plan”) (collectively, the “Prior Plans”) that were previously in effect. Following the approval of the Omnibus Plan on April 20, 2020, no further awards were available to be issued under the Prior Plans, but awards outstanding under those plans as of that date remain outstanding in accordance with their terms. As of June 30, 2022, 27,150 and 2,438 shares were subject to outstanding awards under the 2009 Plan and Vical Plan, respectively. On May 17, 2022, the Company’s stockholders approved an increase in the number of shares of common stock authorized for issuance under the Omnibus Plan by 119,377 shares. As of June 30, 2022, 323,364 shares were authorized and 202,496 shares were subject to outstanding awards under the Omnibus Plan. As of June 30, 2022, 125,075 shares remained available for grant under the Omnibus Plan. Employee Stock Purchase Plan On April 19, 2021, the Company’s stockholders approved the ESPP, which had a first eligible purchase period commencing on July 1, 2021. The ESPP allows qualified employees to purchase shares of the Company’s common stock at a price per share equal to 85% of the lower of: (i) the closing price of the Company’s common stock on the first trading day of the applicable purchase period or (ii) the closing price of the Company’s common stock on the last trading day of the applicable purchase period. New six-month purchase periods begin each January 1 and July 1. As of June 30, 2022, the Company had 48,484 shares available for issuance and 9,293 cumulative shares had been issued under the ESPP. Stock-Based Compensation Expense Total stock-based compensation expense reported in the condensed consolidated statements of operations was allocated as follows (in thousands): Three Months Ended Six Months Ended 2022 2021 2022 2021 Research and development $ 113 $ 88 $ 216 $ 197 General and administrative 463 333 911 693 Total stock-based compensation expense $ 576 $ 421 $ 1,127 $ 890

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS At Market Issuance Sales Agreements Subsequent to June 30, 2022, the Company sold shares of common stock under the 2021 ATM Agreement for aggregate net proceeds of approximately $0.7 million. Nasdaq Minimum Bid Price Compliance On July 19, 2022, the Company received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that it regained compliance with the minimum bid price requirement for continued listing on Nasdaq and, accordingly, that the previously-scheduled hearing regarding the delisting action had been canceled and the Company’s common stock will continue to be listed and traded on Nasdaq.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc. (“Brickell Subsidiary”), and are presented in United States (“U.S.”) dollars and have been prepared in accordance with accounting principles generally accepted in the
Use of Estimates	Use of Estimates The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.
Fair Value Measurements	Fair Value Measurements Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market, or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy distinguishes between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs). The hierarchy is summarized in the three broad levels listed below: Level 1 —quoted prices in active markets for identical assets and liabilities Level 2 —other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.) Level 3 —significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities) Fair Value of Financial Instruments The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein: Money Market Funds— The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy). The carrying values of cash equivalents, other current assets, accounts payable, and accrued liabilities approximate fair value due to the short-term maturity of those items.
Revenue Recognition	Revenue Recognition The Company has recognized revenue primarily from royalty fees received under the Kaken Agreement and upfront fees, research reimbursements, and sublicense income received under the Asset Purchase Agreement described in Note 4. “ Strategic Agreements. ” The terms of the agreements may include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones, and various sales-based payments. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company utilizes judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Contract Revenue The Company evaluates its contracts, including asset sale arrangements that involve the Company’s rights to intellectual property, to determine whether they are outputs of the Company’s ordinary activities and whether the counterparty meets the definition of a customer. If the arrangement is determined to be a contract with a customer and the goods or services sold are determined to be distinct from other performance obligations identified in the arrangement, the Company recognizes revenue primarily from non-refundable upfront fees, milestone payments, and sales-based payments allocated to the goods or services when (or as) control is transferred to the customer, and the customer can use and benefit from the goods or services. Licenses of Intellectual Property If a license for the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue when the license is transferred to the customer, and the customer can use and benefit from the license. Milestones At the inception of each arrangement that includes milestone payments (variable consideration), excluding sales-based milestone payments discussed below, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. The most likely amount method is generally utilized when there are only two possible outcomes and represents the Company’s best estimate of the single most likely outcome to be achieved. If it is probable that a significant revenue reversal would not occur, the variable consideration for the associated milestone is included in the transaction price. Milestone payments contingent on regulatory approvals that are not within the Company and the Company’s collaboration partner’s control, as applicable, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjusts the Company’s estimate of the variable consideration. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment. Sales-Based Payments For license arrangements that include sales-based payments such as royalties or milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the sales-based payments relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the sales-based payment has been allocated has been satisfied (or partially satisfied). Sales-based payments received under license arrangements are recorded as royalty revenue in the Company’s condensed consolidated statements of operations. For non-license arrangements that include sales-based payments, including earnout payments and milestone payments based on the level of sales, the Company estimates the sales-based payments (variable consideration) to be achieved and recognizes revenue to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company may use either the most likely amount, as described above, or the expected value method, in making such estimates based on the nature of the payment to be received and whether there is a wide range of outcomes or only two possible outcomes. The expected value method represents the sum of probability-weighted amounts in a range of possible consideration amounts. The Company bases its estimates using the applicable method described above on factors such as, but not limited to, required regulatory approvals, historical sales levels, market events and projections, and other factors as appropriate. The Company updates its estimates at each reporting period based on actual results and future expectations as necessary. Contract Asset
Research and Development	Research and Development Research and development costs are charged to expense when incurred and consist of costs incurred for independent and collaboration research and development activities. The major components of research and development costs include formulation development, nonclinical studies, clinical studies, clinical manufacturing costs, in-licensing fees for development-stage assets, salaries and employee benefits, and allocations of various overhead and occupancy costs. Research costs typically consist of applied research, preclinical, and toxicology work. Pharmaceutical manufacturing development costs consist of product formulation, chemical analysis, and the transfer and scale-up of manufacturing at contract manufacturers. Assets acquired (or in-licensed) that are utilized in research and development that have no alternative future use are expensed as incurred. Milestone payments related to the Company’s acquired (or in-licensed) assets are recorded as research and development expenses when probable and reasonably estimable. The Company has entered into and may continue to enter into licensing or subscription arrangements to access and utilize certain technology. In each case, the Company evaluates if the license agreement results in the acquisition of an asset or a business. To date, none of the Company’s license agreements have been considered an acquisition of a business. For asset acquisitions, the upfront payments to acquire such licenses, as well as any future milestone payments made before product approval that do not meet the definition of a derivative, are immediately recognized as research and development expenses when they are paid or become payable, provided there is no alternative future use of the rights in other research and development projects.
Clinical Trial Accruals	Clinical Trial Accruals Expense accruals related to clinical trials are based on the Company’s estimates of services received and efforts expended pursuant to contracts with multiple research institutions and third-party clinical research organizations that conduct and manage clinical trials on the Company’s behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing costs, the Company estimates the period over which services will be performed and the level of effort to be expended in each period based upon patient enrollment, clinical site activations, or information provided to the Company by its vendors on their actual costs incurred. Any estimates of the level of services performed or the costs of these services could differ from actual results.
Net Loss per Share	Net Loss per Share (Restated) Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net income by the weighted-average number of common shares outstanding and the
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company does not currently hold any financing leases. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of one year or less and not to separate lease components and non-lease components for long-term real estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate in determining the present value of lease payments. The Company’s headquarters operating lease has one single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations.
Redeemable Preferred Stock	Redeemable Preferred Stock The Company issued one share of redeemable preferred stock in May 2022. The redeemable preferred stock contained provisions that required redemption under circumstances that were outside of the Company’s control and was classified as a mezzanine instrument outside of the Company’s capital accounts. The share of redeemable preferred stock was sold to one investor for $10 and was subsequently redeemed in July 2022, as described further in Note 8. “ Capital Stock. ”
New Accounting Pronouncements	New Accounting PronouncementsFrom time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that the Company adopts as of the specified effective date. The Company does not believe that the adoption of recently issued standards has had or will have a material impact on the Company's condensed consolidated financial statements or disclosures

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Changes and Error Corrections [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The following table illustrates the impact of the restatement of basic and diluted net loss per common share attributable to common stockholders on the condensed consolidated statements of operations: Three Months Ended Six Months Ended 2022 2021 2022 2021 As previously reported $ (0.01) $ (0.16) $ (0.09) $ (0.31) Adjustment $ (0.42) $ (7.13) $ (3.89) $ (13.72) As restated $ (0.43) $ (7.29) $ (3.98) $ (14.03) The following table illustrates the impact of the restatement of common stock par value and additional paid-in capital on the condensed consolidated balance sheets: June 30, 2022 December 31, 2021 Common Stock Additional Paid-In Capital Common Stock Additional Paid-In Capital As previously reported $ 1,211 $ 170,350 $ 1,194 $ 169,080 Adjustment (1,184) 1,184 (1,167) 1,167 As restated $ 27 $ 171,534 $ 27 $ 170,247

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Fair Value Measurements, Recurring and Nonrecurring	The following table sets forth the fair value of the Company’s financial assets measured at fair value on a recurring basis based on the three-tier fair value hierarchy (in thousands): Level 1 June 30, December 31, Assets: Money market funds $ 13,480 $ 25,875
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table sets forth the potential common shares excluded from the calculation of diluted net loss per share because their inclusion would be anti-dilutive: Three and Six Months Ended 2022 2021 Outstanding warrants 621,063 621,063 Outstanding options 232,084 149,248 Unvested restricted stock units — 1,054 Total 853,147 771,365

DETAILED ACCOUNT BALANCES (Tabl

DETAILED ACCOUNT BALANCES (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Prepaid Expenses	Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, Prepaid clinical trial costs $ 2,390 $ 1,443 Prepaid insurance 694 921 Accounts receivable 358 125 Other prepaid expenses 170 168 Contract asset 152 — Other short-term assets 7 59 Total $ 3,771 $ 2,716
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): June 30, December 31, Accrued compensation $ 1,016 $ 1,861 Accrued professional fees 382 452 Accrued contracted research and development services 173 823 Total $ 1,571 $ 3,136

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Obligations	The following is a summary of the contractual obligations related to operating lease commitments as of June 30, 2022 (in thousands): Total maturities, through December 31, 2022 $ 37 Less imputed interest (1) Present value of lease liability $ 36

CAPITAL STOCK (Tables)

CAPITAL STOCK (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Reserved Authorized Shares of Common Stock	The Company had reserved authorized shares of common stock for future issuance as of June 30, 2022 as follows: June 30, Common stock warrants 621,063 Common stock options outstanding 232,084 Shares available for grant under the Omnibus Plan 125,075 Shares available for grant under the Employee Stock Purchase Plan 48,484 Total 1,026,706

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Share-Based Compensation Expense	Total stock-based compensation expense reported in the condensed consolidated statements of operations was allocated as follows (in thousands): Three Months Ended Six Months Ended 2022 2021 2022 2021 Research and development $ 113 $ 88 $ 216 $ 197 General and administrative 463 333 911 693 Total stock-based compensation expense $ 576 $ 421 $ 1,127 $ 890

ORGANIZATION AND NATURE OF OP_2

ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details) $ in Thousands		1 Months Ended	3 Months Ended				6 Months Ended
	Jul. 05, 2022	Aug. 11, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	May 03, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss			$ 1,147	$ 9,410	$ 11,149	$ 9,005	$ 10,557	$ 20,154
Net cash used in operating activities							12,509	20,205
Cash and cash equivalents			14,480				14,480			$ 26,884
Accumulated deficit			155,924				155,924			$ 145,367
Proceeds from the exercise of warrants							0	$ 8,969
Subsequent Event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock split, conversion ratio	0.0222
Pre-Funded Warrant | Subsequent Event | 2020 At Market Issuance Sales Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from the exercise of warrants		$ 700
Botanix
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability									$ 3,000
Botanix | Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount									$ 2,000
Botanix | Milestone Payments | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount			$ 2,000				$ 2,000

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Narrative (Details)	Jul. 05, 2022
Subsequent Event
Change in Accounting Estimate [Line Items]
Stock split, conversion ratio	0.0222

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Impact of the Restatement of Basic and Diluted Net Loss per Common Share Attributable to Common Stockholders (Details) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Change in Accounting Estimate [Line Items]
Net loss per common share attributable to common stockholders, basic (in usd per share)	$ (0.43)	$ (7.29)	$ (3.98)	$ (14.03)
Net loss per common share attributable to common stockholders, diluted (in usd per share)	(0.43)	(7.29)	(3.98)	(14.03)
Previously Reported
Change in Accounting Estimate [Line Items]
Net loss per common share attributable to common stockholders, basic (in usd per share)	(0.01)	(0.16)	(0.09)	(0.31)
Net loss per common share attributable to common stockholders, diluted (in usd per share)	(0.01)	(0.16)	(0.09)	(0.31)
Revision of Prior Period, Adjustment
Change in Accounting Estimate [Line Items]
Net loss per common share attributable to common stockholders, basic (in usd per share)	(0.42)	(7.13)	(3.89)	(13.72)
Net loss per common share attributable to common stockholders, diluted (in usd per share)	$ (0.42)	$ (7.13)	$ (3.89)	$ (13.72)

RESTATEMENT OF PREVIOUSLY ISS_5

RESTATEMENT OF PREVIOUSLY ISSUED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Impact of the Restatement of Common Stock and Additional Paid-in Capital (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Change in Accounting Estimate [Line Items]
Common Stock	$ 27	$ 27
Additional paid-in capital	171,534	170,247
Revision of Prior Period, Adjustment
Change in Accounting Estimate [Line Items]
Common Stock	(1,184)	(1,167)
Additional paid-in capital	1,184	1,167
Previously Reported
Change in Accounting Estimate [Line Items]
Common Stock	1,211	1,194
Additional paid-in capital	$ 170,350	$ 169,080

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)	6 Months Ended
	Jun. 30, 2022 USD ($) segment
Accounting Policies [Abstract]
Number of operating segments | segment	1
Proceeds from issuance of redeemable preferred stock | $	$ 10

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Recurring | Fair Value, Inputs, Level 1
Assets:
Money market funds	$ 13,480	$ 25,875

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the calculation of EPS	853,147	771,365	853,147	771,365
Outstanding warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the calculation of EPS	621,063	621,063	621,063	621,063
Outstanding options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the calculation of EPS	232,084	149,248	232,084	149,248
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded from the calculation of EPS	0	1,054	0	1,054

STRATEGIC AGREEMENTS (Details)

STRATEGIC AGREEMENTS (Details)			3 Months Ended		6 Months Ended
	May 03, 2022 USD ($) shares	Aug. 27, 2021 USD ($) shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Feb. 02, 2022 USD ($)	Dec. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense, future payment, payment two		$ 107,500,000
Milestone payment		1,000,000
Total revenue			$ 4,315,000	$ 151,000	$ 4,407,000	$ 168,000
Contract asset			152,000		152,000			$ 0
Research and development			1,865,000	8,838,000	7,878,000	14,890,000
General and administrative			3,908,000	2,891,000	7,394,000	5,858,000
Royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			0	151,000	92,000	168,000
Royalty revenue | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue					100,000
Carna Biosciences, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, one-time cash payment							$ 2,000,000
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments							$ 258,000,000
Collaborative arrangement, rights and obligations, royalty payments, percent of net sales							0.10
Voronoi Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payments to acquire intangible assets		2,500,000
Issuance of common stock under license agreement		$ 2,000,000
Issuance of common stock under license agreement (in shares) | shares		62,597
Research and development expense, future payment, payment one		$ 211,000,000
Kaken | Milestone Payments | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	$ 10,000,000
Kaken | Royalty revenue | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	19,000,000
Botanix
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract with customer, liability	$ 3,000,000
Collaborative agreement, administration fee percentage	5%
Shares authorized | shares	1,000,000
Research and development			0	0	0	0
Botanix | Payment Criteria Three
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	$ 168,000,000
Botanix | Milestone Payments
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	2,000,000
Botanix | Milestone Payments | Payment Criteria Two
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	2,500,000
Botanix | Milestone Payments | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount			2,000,000		2,000,000
Botanix | Milestone Payments | Maximum | Payment Criteria One
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue, remaining performance obligation, variable consideration amount	4,000,000
Botanix | Royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			0	$ 200,000		$ 200,000
Botanix | Upfront Fee
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			3,000,000
Botanix | Reimbursable Development Expenditures
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue					600,000
Botanix | Consulting Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, monthly payment to be received	$ 71,000
Botanix | Consulting Services | Collaborative Arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue			400,000		400,000
Botanix | Sublicense Income
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenue					300,000
Botanix | Sublicense Income | Prepaid Expenses and Other Current Assets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contract asset			200,000		200,000
Bodor Laboratories, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative agreement, percentage of actual fees to be paid	18%
General and administrative			$ 500,000		$ 500,000

DETAILED ACCOUNT BALANCES - Sum

DETAILED ACCOUNT BALANCES - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Prepaid clinical trial costs	$ 2,390	$ 1,443
Prepaid insurance	694	921
Accounts receivable	358	125
Other prepaid expenses	170	168
Contract asset	152	0
Other short-term assets	7	59
Prepaid expenses and other current assets	$ 3,771	$ 2,716

DETAILED ACCOUNT BALANCES - S_2

DETAILED ACCOUNT BALANCES - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued compensation	$ 1,016	$ 1,861
Accrued professional fees	382	452
Accrued contracted research and development services	173	823
Total	$ 1,571	$ 3,136

NOTE PAYABLE - Narrative (Detai

NOTE PAYABLE - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Apr. 15, 2020
Debt Instrument [Line Items]
Gain on extinguishment of debt	$ 0	$ 437
Paycheck Protection Program
Debt Instrument [Line Items]
Face amount			$ 400
Stated rate			1%

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details)	6 Months Ended
	Jun. 30, 2022 USD ($) renewalTerm
Commitments and Contingencies Disclosure [Abstract]
Number of additional terms | renewalTerm	2
Renewal term	3 years
Monthly payment, thereafter | $	$ 6,076
Discount rate	11%
Extended lease term	18 months

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Schedule of Contractual Obligations (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Total maturities, through December 31, 2022	$ 37
Less imputed interest	(1)
Present value of lease liability	$ 36

CAPITAL STOCK - Narrative (Deta

CAPITAL STOCK - Narrative (Details)		1 Months Ended						3 Months Ended		6 Months Ended
	Jul. 05, 2022	Aug. 11, 2022 USD ($)	Oct. 31, 2021 USD ($) $ / shares shares	Jul. 31, 2021 USD ($) $ / shares shares	Oct. 31, 2020 USD ($) $ / shares shares	Jun. 30, 2020 USD ($) $ / shares shares	Feb. 29, 2020 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) vote $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	May 25, 2022 shares	Dec. 31, 2021 $ / shares shares	Mar. 31, 2021 USD ($)	Apr. 30, 2020 USD ($)
Class of Stock [Line Items]
Common stock, shares authorized								300,000,000		300,000,000			300,000,000
Common stock, par value (in usd per share) | $ / shares								$ 0.01		$ 0.01			$ 0.01
Sale of stock, expiration term					5 years
Proceeds from the exercise of warrants | $										$ 0	$ 8,969,000
Common stock, shares issued								2,690,360		2,690,360			2,652,828
Aggregate purchase price for stock and warrants | $						$ 200,000
Sale of stock, percentage of commission											0.03
Sale of stock additional shares authorized amount | $								$ 26,900,000		$ 26,900,000
Temporary equity, shares authorized								5,000,000		5,000,000			5,000,000
Temporary equity, par or stated value per share (in dollars per share) | $ / shares								$ 0.01		$ 0.01			$ 0.01
Preferred stock, shares outstanding												1
Preferred stock, outstanding, votes | vote										80,000,000
Sale of stock, registered stock										57,751
Sale of stock, registered shares, amount | $										$ 175,000
Subsequent Event
Class of Stock [Line Items]
Stock split, conversion ratio	0.0222
Lincoln Park
Class of Stock [Line Items]
Purchase obligation | $							$ 28,000,000
Purchase obligation, term							36 months
Maximum commitment purchase amount | $							$ 1,000,000
Percentage of ownership after transaction							9.99%
Common stock warrants
Class of Stock [Line Items]
Exercise price (in usd per share) | $ / shares									$ 32.40		$ 32.40
Pre-Funded Warrant
Class of Stock [Line Items]
Exercise price (in usd per share) | $ / shares					$ 0.04	$ 0.04
October 2021 Offering
Class of Stock [Line Items]
Number of shares issued in transaction			672,521
Closing sale price (in usd per share) | $ / shares			$ 17.10
Consideration received on transaction | $			$ 10,300,000
July 2021 Offering
Class of Stock [Line Items]
Number of shares issued in transaction				288,530
Closing sale price (in usd per share) | $ / shares				$ 27.90
Consideration received on transaction | $				$ 7,300,000
October 2020 Offering
Class of Stock [Line Items]
Consideration received on transaction | $					$ 13,700,000
Number of shares authorized to be repurchased					462,979
Exercise price (in usd per share) | $ / shares									$ 32.40		$ 32.40
Commissions discounts and other offering expenses | $					$ 1,300,000
Stock issuable upon warrants (in shares)									(276,165)		(276,165)
Proceeds from the exercise of warrants | $											$ 8,900,000
October 2020 Offering | Common Stock
Class of Stock [Line Items]
Number of shares issued in transaction					422,300
October 2020 Offering | Common stock warrants
Class of Stock [Line Items]
Closing sale price (in usd per share) | $ / shares					$ 32.40
Number of shares authorized to be repurchased					40,663
Class of warrant or right, number of securities called by each warrant or right (in shares)					1
October 2020 Offering | Pre-Funded Warrant
Class of Stock [Line Items]
Closing sale price (in usd per share) | $ / shares					$ 32.35
Common Stock Public Offering
Class of Stock [Line Items]
Exercise price (in usd per share) | $ / shares						$ 56.25			$ 56.25		$ 56.25
Sale of stock, expiration term						5 years
Stock issuable upon warrants (in shares)									(388)		(388)
Proceeds from the exercise of warrants | $											$ 22,000
Common stock, shares issued						328,669
Net proceeds from common stock public offering | $						$ 18,700,000
Underwriting commissions, discounts, and other offering expenses | $						$ 1,400,000
Common Stock Public Offering | Pre-Funded Warrant
Class of Stock [Line Items]
Class of warrant or right, number of securities called by each warrant or right (in shares)						1
Stock issuable upon warrants (in shares)						(60,220)
Public offering price (in usd per share) | $ / shares						$ 51.75
Common Stock Public Offering | Accompanying Common Warrant
Class of Stock [Line Items]
Stock issuable upon warrants (in shares)						(388,920)
Public offering price (in usd per share) | $ / shares						$ 51.70
2021 At Market Issuance Sales Agreement
Class of Stock [Line Items]
Number of shares issued in transaction								31,557	88,077	31,557	88,077
Closing sale price (in usd per share) | $ / shares								$ 5.61	$ 40.18	$ 5.61	$ 40.18
Consideration received on transaction | $								$ 200,000	$ 3,400,000	$ 200,000	$ 3,400,000
Aggregate offering price | $														$ 50,000,000
Shares remaining to be sold, amount | $								$ 45,900,000		$ 45,900,000
2020 At Market Issuance Sales Agreement
Class of Stock [Line Items]
Number of shares issued in transaction								0	122	0
Closing sale price (in usd per share) | $ / shares									$ 52.25		$ 52.25
Consideration received on transaction | $									$ 6,200
Aggregate offering price | $															$ 8,000,000
2020 At Market Issuance Sales Agreement | Pre-Funded Warrant | Subsequent Event
Class of Stock [Line Items]
Proceeds from the exercise of warrants | $		$ 700,000
2020 At Market Issuance Sales Agreement Scenario 2
Class of Stock [Line Items]
Number of shares issued in transaction											24,201
Closing sale price (in usd per share) | $ / shares									$ 69.62		$ 69.62
Consideration received on transaction | $											$ 1,600,000
Sale of stock additional shares authorized amount | $								$ 2,600,000		$ 2,600,000
Private Placement Offerings
Class of Stock [Line Items]
Common stock, shares issued							21,111
Aggregate gross purchase price | $							$ 2,000,000
Private Placement Offerings | Series A
Class of Stock [Line Items]
Exercise price (in usd per share) | $ / shares							$ 0.45
Stock issuable upon warrants (in shares)							(13,476)
Private Placement Offerings | Series B
Class of Stock [Line Items]
Exercise price (in usd per share) | $ / shares							$ 52.20
Stock issuable upon warrants (in shares)							(34,588)
Purchase Agreement | Lincoln Park
Class of Stock [Line Items]
Number of shares issued in transaction										17,778	17,778
Closing sale price (in usd per share) | $ / shares							$ 3
Consideration received on transaction | $										$ 600,000	$ 600,000
Maximum shares allowed to be purchased							2,222
Maximum share increase amount							2,777
Sale of stock, weighted average price per share (in usd per share) | $ / shares										$ 36.62	$ 36.62
Regular Purchase | Lincoln Park
Class of Stock [Line Items]
Closing sale price (in usd per share) | $ / shares							$ 5
Maximum share increase amount							3,333

CAPITAL STOCK - Reserved Author

CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details) - shares	Jun. 30, 2022	May 03, 2022
Class of Stock [Line Items]
Shares of common stock reserved for future issuance	1,026,706
Outstanding warrants
Class of Stock [Line Items]
Shares of common stock reserved for future issuance	621,063
Common stock options outstanding
Class of Stock [Line Items]
Shares of common stock reserved for future issuance	232,084
Outstanding options | 2020 Omnibus Plan
Class of Stock [Line Items]
Shares available for grant	125,075	323,364
Employee Stock
Class of Stock [Line Items]
Shares available for grant	48,484

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - shares		6 Months Ended	14 Months Ended
	May 17, 2022	Jun. 30, 2022	Jun. 30, 2022	May 03, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock purchase offering period		6 months
2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized	119,377
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period			9,293
Outstanding options | 2009 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)		27,150	27,150
Outstanding options | Vical Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)		2,438	2,438
Outstanding options | 2020 Omnibus Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)		202,496	202,496
Shares available for grant		125,075	125,075	323,364
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant		48,484	48,484
Employee Stock | Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Discount from market price, purchase date		85%

STOCK-BASED COMPENSATION - Shar

STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 576	$ 421	$ 1,127	$ 890
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	113	88	216	197
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 463	$ 333	$ 911	$ 693

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Aug. 11, 2022	Jun. 30, 2022	Jun. 30, 2021
Subsequent Event [Line Items]
Proceeds from the exercise of warrants		$ 0	$ 8,969
Pre-Funded Warrant | Subsequent Event | 2020 At Market Issuance Sales Agreement
Subsequent Event [Line Items]
Proceeds from the exercise of warrants	$ 700